---
title: "Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291180718.md"
datetime: "2026-06-29T18:54:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291180718.md)
  - [en](https://longbridge.com/en/news/291180718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291180718.md)
---

# Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC

June 29 (Reuters) - \* ELI LILLY, REGENERON AMONG FIRST COMPANIES SELECTED FOR FDA INITIATIVE TO SPEED REVIEW OF NEW MANUFACTURING FACILITIES - CNBC Source text: https://tinyurl.com/yh3mzsua Further company coverage: (LLY.N)

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [TRI.US](https://longbridge.com/en/quote/TRI.US.md)

## Related News & Research

- [Lilly Targets Early 2027 Filing for Next Obesity Drug](https://longbridge.com/en/news/293649982.md)
- [Eli Lilly's Retatrutide Meets Primary Endpoint In Phase 3 TRIUMPH-2 And TRIUMPH-3 Trials](https://longbridge.com/en/news/293605576.md)
- [Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application](https://longbridge.com/en/news/293600518.md)
- [Gallacher Capital Management LLC Decreases Stake in Eli Lilly and Company $LLY](https://longbridge.com/en/news/293094450.md)
- [Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials](https://longbridge.com/en/news/293607076.md)